4-benzyloxysemicarbazide | 1226693-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyloxysemicarbazide
• 英文别名: 1-amino-3-phenylmethoxyurea
• CAS: 1226693-11-3
• 化学式: C₈H₁₁N₃O₂
• 分子量: 181.194
• InChiKey: DNCWZYDRHWXUJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-benzyloxysemicarbazide 在 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.33h， 生成 5-benzyloxycarbamoyl-1-[2-(4-isobutylphenyl)propanoyl]carbazide
  参考文献：
  名称：

  Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants

  摘要：

  The novel 1-acyl-4-cycloalkyl/arylsemicarbazides (5a-y) and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides (8a-f) derived from the nonsteroidal anti-inflammatory drugs ibuprofen, fenoprofen and reduced ketoprofen were prepared, fully chemically characterized and evaluated for their cytostatic, antiviral and antioxidant activities. Compounds 5 and 8 consist of a region rich in electronegative atoms (five to nine nitrogen and oxygen atoms) framed by aryl or cycloalkyl residues on one or both terminal ends. The synthetic pathways applied for the preparation of the title compounds involved a benzotriazole as a synthetic auxiliary in several steps. Three of the tested compounds, namely 4-benzhydryl-1-[2-(3-phenoxyphenyl)propanoyl]semicarbazide (5l), 4-benzhydryl-1-[2-(3-benzylphenyl)propanoyl]semicarbazide (5s), and 4-benzhydryl-1-[2-(4-isobutylphenyl)propanoyl]semicarbazide (5f) showed pronounced antiproliferative activity in vitro against six cancer cell lines (IC50 = 3-23 mu M). The same compounds highly inhibited soybean lipoxygenase (IC50 = 60 and 51.5 mu M) and lipid peroxidation as well (99, 88 and 74%, respectively). 4-Benzyloxy-1-[2-(4-isobutylphenyl)propanoyl]semicarbazide (5t) and 5-benzyloxycarbamoyl-1-[2-(3-benzylphenyl)propanoyl]carbazide (8c) exerted complete lipid peroxidation inhibition. Semicarbazides 5w-y and carbazides 8d-f bearing a hydroxamic acid/hydroxyurea moiety showed a modest antiradical activity in DPPH test, while the best radical scavenger was 1-(1-benzotriazolecarbonyl)-4-benzyloxysemicarbazide (7). None of the compounds were inhibitory to a broad panel of DNA and RNA viruses in the cell culture at subtoxic concentrations. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.046
• 作为产物：
  描述：

  N-benzyloxy-1H-benzotriazole-1-carboxamide 在 一水合肼 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 生成 4-benzyloxysemicarbazide
  参考文献：
  名称：

  伯氨喹的新型1-酰基-4-取代的氨基脲衍生物-合成，细胞抑制，抗病毒和抗氧化研究。

  摘要：

  制备一系列新颖的1，4-取代的氨基脲5a-g，其具有在位置1的羰基桥接的伯氨喹部分和在位置4的环烷基，芳基，苄氧基或羟基取代基，并进行了生物学评估。用于制备标题化合物的合成途径涉及苯并三唑作为合成助剂。评估了伯氨喹氨基脲5a-g及其合成前体苯并三唑羰基氨基脲4的抑制细胞生长，抗病毒和抗氧化活性。第5系列的所有化合物均对MCF-7细胞（乳腺癌）表现出高选择性，IC（50）值在低微摩尔范围内，而活性最高的是苄基衍生物5c（IC（50）1±0.2 µM）。苯甲酰基衍生物5e对所有测试的细胞系（IC（50）4-18 µM）均显示出显着的细胞抑制活性。同样的化合物也是最强的脂氧合酶抑制剂（51％）。羟基衍生物5g和苯并三唑羰基氨基脲4b，c（61.2-68.5％）的抗氧化剂活性最高。没有观察到针对多种DNA和RNA病毒的抗病毒活性。

  DOI：

  10.3109/14756366.2012.663366

文献信息

• Facile Synthesis and In-Vitro Antimalarial Activity of Novel α-Hydroxy Hydrazonates
  作者：Mehdi Khankischpur、Finn K. Hansen、Ronald Meurer、Tobias Mauz、Baerbel Bergmann、Rolf D. Walter、Detlef Geffken

  DOI：10.1002/ardp.201000346

  日期：2011.11

  A series of previously unreported α‐hydroxy hydrazonates were synthesized and tested for their antimalarial properties. Structure optimization of the antiplasmodially active α‐hydroxy hydrazonate III furnished derivatives with strong in‐vitro antimalarial activity against 3D7 strains of Plasmodium falciparum with IC50 values lower than 2.0 µM.

  合成了一系列以前未报道的 α-羟基腙，并测试了它们的抗疟特性。抗疟原虫活性α-羟基腙III的结构优化提供了对恶性疟原虫3D7菌株具有强体外抗疟活性的衍生物，IC50值低于2.0 µM。
• NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY
  申请人：Song Yongcheng

  公开号：US20130065857A1

  公开（公告）日：2013-03-14

  The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

  本发明通常涉及特定的抗微生物治疗方法和组合物。在特定实施例中，该组合物针对DXR。在具体实施例中，该组合物是电子不足的杂环环。